Allena begins Phase II trial of ALLN-177 in patients with secondary hyperoxaluria

US-based Allena Pharmaceuticals has started its 28-day Phase II trial of ALLN-177, an orally administered recombinant oxalate-degrading enzyme, and potential treatment for hyperoxaluria and kidney stones.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news